Our portfolio
Archaogen

Antibacterial drug development

Achaogen focuses on the R&D and commercialization of antibacterials to combat multi-drug-resistant, Gram-negative infections. The foundation’s investment supports the development of Achaogen’s monoclonal antibody (mAb) discovery platform.
  • Domain
    Life Sciences
  • Investment type
    Direct equity
  • Status
    Exit
  • Initial investment
    Public
  • Partnered in
    2017
  • Headquarters
    USA
  • Program strategy
    Discovery & Translational Sciences

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.